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ABSTRACT
Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder commonly seen in females characterized by multisystem inflammation with 
the production of an array of antibodies. Hematological disturbances are common in SLE specifically autoimmune hemolytic anemia (AIHA) which 
results from the development of autoantibodies directed against antigens on the surface of patient’s own red blood cells. Here, we present a rare case 
of a 50-year-old female patient presenting with cold antibody-mediated AIHA.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease 
commonly affecting women. SLE is a systemic autoimmune disorder 
characterized by multisystem inflammation with the production 
of an array of antibodies. Serum nuclear antibodies (antinuclear 
antibody [ANA]) are found in nearly all individuals with active SLE [1]. 
Autoimmune hemolytic anemia (AIHA) in SLE is usually mediated by 
warm immunoglobulin G anti-erythrocyte antibodies [2]. However, 
here, we report a female patient who was a known case of SLE, 
presented with cold antibody-mediated AIHA.
CASE REPORT
There was no history of autoimmune disease in other family members.
On examination, the patient was conscious and well oriented. 
Pallor was present, and there were no icterus, no clubbing, and no 
lymphadenopathy. Cyanosis of the fingers of the left hand was present. 
Her blood pressure was 110/70 mmHg, pulse 84 beats/min, respiratory 
rate 18/min, temperature 98°F, and SpO2 98% on room air. Her chest 
was clear, and the abdomen was soft, non-distended, and non-tender 
with no organomegaly. Cardiovascular system examination was normal.
Investigations
Her initial laboratory workup revealed peripheral smear showing 
spherocytosis. Serum bilirubin: Total - 1.41 mg/dl, direct - 0.09 mg/dl, 
indirect - 1.32 mg/dl, alkaline phosphatase - 73 IU/L (normal <130 IU/L), 
alanine aminotransferase - 17 IU/L (normal <40 IU/L), aspartate 
aminotransferase - 63 IU/L (normal <40 IU/L), erythrocyte sedimentation 
rate - 60 mm/h, serum albumin - 4.21 g%, hemoglobin - 2.4 g/dl, total 
white blood cell - 8800/mm3, differential count - PMN 79.9/L 12.6/E 
2.2/M 4.7%, and platelet count - 309,000/mm3. Peripheral smear 
showed extensive red blood cell (RBC) clumping as shown in Fig. 1.
ANA immunofluorescence on human epithelial type 2 and rat liver 
cells showed nucleus granular pattern (+++) with a titer of >1:320. 
The ANA profile showed Ro-52 (+++), dsDNA +++, Sm (+), and 
SS-B (+). Antineutrophil cytoplasmic antibody immunofluorescence 
was negative.
The laboratory workup for infections including viral hepatitis, 
tuberculosis, and HIV was negative. In view of dysphagia, 
ultrasonography was done, which revealed lax esophagogastric junction 
with duodenogastric reflux and suggested to do manometry. Manometry 
revealed abnormal contractility. Workup for hemolysis showed cold 
antibody positive. The case was diagnosed as SLE overlap syndrome 
(SLE with Sjogren’s syndrome and Raynaud’s phenomenon) with severe 
anemia mediated by cold autoantibodies and esophageal dysmotility.
Treatment
The patient was on methotrexate 15 mg/week for joint pain for 1 year. 
Initially, she was treated with prednisolone 1 mg/kg, but the patient 
continued to have hemolysis, and there was no improvement. Then, 
after review of literature, rituximab was considered as an option. The 
patient was treated for SLE-related intravascular hemolysis. Three 
units of packed RBC (PRBC) transfusions were given under warmer 
in view of dropping hemoglobin. However, treatment with steroids 
proved ineffective and the patient required further blood transfusions 
for symptomatic anemia. Rituximab was initiated resulting in 
significant clinical improvement. Her hemoglobin improved from 
3.8 g/dl to 12 g/dl. The patient was subsequently discharged from the 
hospital.
Outcome and follow-up
The patient was continued on rituximab as outpatient and did not 
require any further blood transfusions. Her follow-up hematocrit 
levels remained stable. Over 1 month follow-up course, she showed 
remarkable improvement in her symptomatology and other clinical 
parameters including normalization of her hemoglobin levels.
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Case Report
A  50-year-old  woman  presented  to  the  department  of 
medicine with dysphagia and passage of  dark stools  for 1 
week.  Dysphagia  started  1  year  back,  and  she  was  diagnosed  as 
SLE/overlap  syndrome  (SLE  Sjogren’s  syndrome  and  Raynaud’s 
phenomenon).  She  was  started  on  steroids,  after  which  the 
symptoms subsided for 2–3 months. Dysphagia started again for 1 
week  which  was  increasing  gradually.  The  patient  complained  of  the 
passage  of  loose  stools  for  7  days,  dark,  sticky,  mucoid,  and  scanty  in 
amount  associated  with  painful  defecation.  The  patient  gives  a 
history of passing blood in urine which increased on exposure to 
cold. She was taken to a local hospital with complaints of fatigue and 
dysphagia and was referred to our tertiary care hospital.
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DISCUSSION
Most patients with SLE develop hematological abnormalities during 
their natural course of the disease. Anemia is found in about 50% of 
patients, and the most common is anemia of chronic disease, followed 
by iron deficiency anemia, AIHA, drug-related myelotoxicity, and 
anemia of chronic kidney disease [2].
Antibody-mediated RBC damage is one of the most common mechanisms 
of anemia in SLE, and it is almost always mediated by warm antibodies. 
Acquired deficiency of RBC CD55 and/or CD59 is associated with AIHA 
in SLE. Similar mechanism can cause autoimmune thrombocytopenia 
and lymphopenia. Immune-mediated marrow failure is another 
mechanism for anemia/pancytopenia. First line of treatment for AIHA 
is prednisone (1 mg/kg/day). Approximately 80% of patients will 
show a dramatic response after 3 weeks, or patients requiring above 
15 mg/day for maintenance are absolute candidates for second-line 
drugs. In idiopathic AIHA, only proven next line treatment with short-
term efficacy is rituximab and splenectomy.
Although extremely rare, cold antibody AIHA in SLE has been 
reported [3,4]. Binding of antibodies to RBCs activates the classical 
pathway of the complement system leading to the formation of membrane 
attack complex and intravascular hemolysis. On the other hand, if classic 
pathway is ineffective, RBCs are opsonized with complement proteins 
(particularly, C3b and C4b) which enhance phagocytosis in the liver 
and spleen, presenting as extravascular hemolysis. In the present case, 
the hemoglobin level was low, suggesting intravascular hemolysis. The 
peripheral blood smear confirmed the diagnosis.
Rituximab has been shown to be very efficacious in the past for AIHA 
with SLE refractory to conventional therapy [5]. Rituximab is also 
known to maintain long-term remission rate in patients with primary 
cold agglutinin AIHA [6,7] and showed rituximab to be extremely 
effective and safe therapeutic alternative in patients with intractable 
and severe AIHA. We used rituximab as our second-line agent. To the 
best of our knowledge, this is, perhaps, the first case report of CA-AIHA 
in a patient with overlap syndrome of SLE and Sjogren’s syndrome.
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Fig. 1: Peripheral blood smear showing extensive red blood cell 
clumping at ×100
